Jul 14th, 2021 - Alpha1-antitrypsin deficiency (AATD) is caused by mutations in the SERPINA1 gene, coding for alpha1-antitrypsin (AAT). AAT is synthesised mainly in the liver and is released into bloodstream to protect tissues (particularly lung) with its antiprotease activity. The homozygous Pi∗Z mutation (Pi∗ZZ genotype) is the predominant cause of severe AATD. It interferes with AAT secretion thereby leading...

May 8th, 2021 - Chronic kidney disease (CKD) affects about 10% of all populations worldwide, with about 2 million people requiring dialysis. Although patients with CKD are at high risk of cardiovascular disease and events, they are often underrepresented or excluded in clinical trials, leading to important knowledge gaps about how to treat these patients. KDIGO (Kidney Disease: Improving Global Outcomes) conve...

Jul 15th, 2020 - Since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection began in December 2019 in Wuhan, China, more than 6 million people have developed coronavirus disease 2019 (COVID-19), and more than 350 000 have died.1 Critical illness from COVID-19 in China, Italy, and other countries has strained intensive care unit (ICU) resources and produced a wide spectrum of sh...

Jul 7th, 2020 - This essential study (Abstract 2003) highlights that health policy impacts cancer survival. It showed that age-adjusted mortality from cancer is worse in states that have not expanded access to Medicaid under the Affordable Care Act. There were 758 fewer cancer deaths in expansion states in 2017, and Hispanic populations had the greatest decrease in mortality under Medicaid expansion. This stud...

Jun 27th, 2020 - The coronavirus disease 2019 (COVID-19) pandemic caused by SARS coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality for patients and stressed healthcare systems worldwide. The clinical features and outcomes of COVID-19 among immunosuppressed patients, who are at presumed risk for more severe disease but who may also have decreased detrimental inflammatory responses, are no...

Jun 25th, 2020 - There used to be a paucity of options for managing advanced renal cell cancer (RCC) with a high toxicity profile including traditional chemotherapy, interferon, and interleukins. With the advent of tyrosine kinase inhibitors (TKIs) in 2007 followed by immunotherapy over the past few years, a paradigm shift emerged in managing this increasingly prevalent disease with its associated high morbidit...

Jun 24th, 2020 - The report on ADAURA during the ASCO20 Virtual Scientific Program Plenary Session surprised many, first because the initial data readout for the phase III trial was not planned until 2022 and second because of the strength of the disclosed data (Abstract LBA5). Early unblinding of the results revealed an 83% reduction in the risk of disease recurrence or death with use of adjuvant osimertinib c...

Jun 1st, 2020 - Meletios A. Dimopoulos, MD, of the University of Athens, discusses phase III results from the BOSTON trial, which showed that once-weekly selinexor, bortezomib, and dexamethasone significantly improved progression-free survival and overall response rates compared with twice-weekly bortezomib and dexamethasone in patients previously treated for multiple myeloma (Abstract 8501).

May 31st, 2020 - Progressing cancer appeared independently associated with increased risk for death among a cohort of patients with malignancies and COVID-19, according to study results presented during the ASCO20 Virtual Scientific Program.

May 31st, 2020 - share to facebook share to twitter share to linkedin email article Including the XPO1 inhibitor selinexor (Xpovio) in a weekly bortezomib (Velcade) regimen improved oncologic outcomes and reduced rates of neuropathy in relapsed or refractory multiple myeloma, the phase III BOSTON trial showed.

May 29th, 2020 - Data from the global TERAVOLT Consortium, which is investigating the impact of COVID-19 infection on patients with thoracic cancers, have found that these patients are at high risk for hospitalization and death. Prior use of chemotherapy was associated with an increased risk of mortality, as was the use of steroids or anticoagulants. Prior administration of immunotherapy and chemoimmunotherapy ...

May 29th, 2020 - Prior use of chemotherapy appeared associated with an increased risk for death among patients with lung or other thoracic cancers and COVID-19, according to study results presented during the ASCO20 Virtual Scientific Program.

May 29th, 2020 - A large cohort study by the COVID-19 and Cancer Consortium evaluating the impact of COVID-19 on patients with cancer has found that all-cause 30-day mortality and severe illness were significantly higher in this population than previously reported in the general population. Mortality and severe illness were associated with general risk factors, as well as those unique to patients with cancer, a...

May 29th, 2020 - States that expanded access to Medicaid under the Affordable Care Act (ACA) in the United States showed a measured cancer survival benefit, and Hispanic patients experienced the greatest decline in mortality, according to a study (Abstract 2003) presented during the ASCO20 Virtual Scientific Program.

May 29th, 2020 - Once-weekly selinexor, bortezomib, and dexamethasone (SVd) for relapsed/refractory multiple myeloma (MM) significantly improved progression-free survival (PFS) and overall response rate (ORR) when compared with twice-weekly bortezomib and dexamethasone (Vd), according to initial results from the phase III BOSTON trial (Abstract 8501).

May 28th, 2020 - An analysis of data collected in the COVID-19 and Cancer Consortium (CCC19) registry showed that patients with progressive cancer were 5.2-times more likely to die within 30 days of being diagnosed with novel coronavirus 19 (COVID-19) compared with patients in remission or with no evidence of disease.

May 28th, 2020 - Chemotherapy administered within 3 months of a diagnosis of coronavirus disease 2019 (COVID-19) increased the risk of death in patients with thoracic cancer, according to findings from the global TERAVOLT Consortium registry.

May 28th, 2020 - Patients with COVID-19 and progressing cancer had a fivefold increase in the risk of 30-day mortality, compared with COVID-19–positive cancer patients who were in remission or had no evidence of cancer, according to data from the COVID-19 and Cancer Consortium (CCC19) registry.

May 28th, 2020 - The risk of death in patients with thoracic cancer was inflated with the administration of chemotherapy within 3 months of a coronavirus disease 2019 (COVID-19) diagnosis, findings from the global TERAVOLT Consortium registry show.

May 28th, 2020 - Death in patients with progressive cancer within 30 days of the coronavirus disease 2019 (COVID-19) diagnosis was 5.2 times compared with patients in remission or with no evidence of disease, data from the COVID-19 and Cancer Consortium (CCC19) registry shows.